Concerned that the U.S. is becoming “overly reliant on sourcing from foreign manufacturers with a demonstrated pattern of repeatedly violating FDA safety regulations,” the House committee has launched its own investigation into the agency’s foreign drug inspection program.
Tag Archive for: China
The United States wants other countries to engage China on limiting the flow of synthetic drugs, the State Department’s top official on narcotics said on Thursday, as Washington complains of a lack of co-operation by Beijing in combating their illegal trade.
China’s Commerce Minister told foreign pharmaceuticals firms they can expect “more development opportunities” during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market.
The vaccine maker said today it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.
Drugmaker AstraZeneca is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunday.
Together, the two organizations will collaborate on helping expand access to innovative healthcare solutions that are available both in and outside of China to ultimately help more patients globally discover new treatment options for a variety of disease states.
Coherus BioSciences Inc. said on Wednesday the U.S. Food and Drug Administration (FDA) had flagged three observations at its partner’s manufacturing site in China when the agency was conducting inspections related to its experimental cancer drug.
The United States on Tuesday imposed sanctions on 17 people and entities based in China and Mexico who it accused of enabling production of counterfeit fentanyl-laced pills, as the Biden administration seeks to stem imports of the deadly drug.
Its establishment of a mainland China unit comes as its revenue growth slows sharply due to waning global demand for its COVID-19 vaccine, the U.S. company’s only approved product.
AstraZeneca on Thursday beat expectations for first-quarter profit and revenue, as buoyant sales of cancer treatment Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling COVID product sales.
